AbbVie (ABBV)
(Delayed Data from NYSE)
$196.82 USD
-0.14 (-0.07%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $196.77 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$196.82 USD
-0.14 (-0.07%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $196.77 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
Biotech Stock Roundup: AbbVie 4Q Results Impress, Ablynx to be Acquired by Sanofi
by Arpita Dutt
While companies like AbbVie (ABBV) were in focus on 4Q earnings results, Ablynx was in the news with the company agreeing to be acquired by French pharma giant, Sanofi.
Lilly (LLY) Beats on Q4 Earnings, Raises 2018 EPS Guidance
by Zacks Equity Research
Lilly (LLY) beats on earnings and sales in Q4 and raises EPS outlook for 2018, reflecting a positive impact of the U.S. tax reform.
Anthem (ANTM) Tops Q4 Earnings & Revenues, Issues '18 View
by Zacks Equity Research
Anthem (ANTM) reported strong fourth-quarter results on the back of solid performance across its segments.
The Zacks Analyst Blog Highlights: Bank of America, Citigroup, AbbVie, 3M, Starbucks and Halliburton
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bank of America, Citigroup, AbbVie, 3M, Starbucks and Halliburton
Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX
by Zacks Equity Research
Two pharma/biotech giants are scheduled to report earnings on Jan 31. Let's take a look at how the companies are placed ahead of the upcoming releases.
HCA Healthcare's (HCA) Q4 Earnings, Revenues Beat Estimates (Revised)
by Zacks Equity Research
HCA Healthcare's (HCA) strong fourth-quarter results were driven by significant growth in admissions.
Novartis' Lutathera Gets FDA Approval for Pancreatic Tumors
by Zacks Equity Research
Novartis' oncology portfolio gets a further boost with the FDA approval of Lutathera for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.
Roche Hemophilia Drug Hemlibra Gets Positive CHMP Opinion
by Zacks Equity Research
Roche announced that it its hemophilia drug Hemlibra obtained a positive opinion from the Committee for Medicinal Products for Human Use in Europe.
AstraZeneca's Triple Combo COPD Inhaler Positive in Phase III
by Zacks Equity Research
AstraZeneca (AZN) announces positive top-line results from the phase III KRONOS study on the triple combination therapy PT010 for severe COPD patients.
Stock Market News for Jan 29, 2018
by Zacks Equity Research
All the three key U.S. indexes closed at record levels on Friday following better-than-expected earnings from Intel, AbbVie and Honeywell
Strength Seen in AbbVie (ABBV): Stock Soars 13.8%
by Zacks Equity Research
AbbVie (ABBV) saw a big move last session, as its shares jumped nearly 14% on the day, amid huge volumes.
AbbVie (ABBV) Soars on Q4 Results: Key Takeaways from the Earnings Call
by Arpita Dutt
With AbbVie (ABBV) surpassing expectations in the fourth quarter, here's a look at a few important takeaways from the company's conference call.
AbbVie (ABBV) Q4 Earnings Beat, 2018 View Raised, Shares Up
by Zacks Equity Research
AbbVie's (ABBV) Q4 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.
A Spate of Q4 Earnings
by Zacks Equity Research
A Spate of Q4 Earnings
Q4 GDP Sub-3%, Q4 Earnings Roll On
by Mark Vickery
The first read for Q4 GDP reached 2.6%, lower than the consensus estimate of 2.9%.
AbbVie (ABBV) Q4 Earnings & Revenues Beat, Guidance Raised
by Zacks Equity Research
AbbVie's (ABBV) fourth-quarter 2017 earnings surpassed estimates with revenues marginally beating the same. Sales of its lead marketed drug Humira also increased compared with the year ago figure.
Novartis Gets Spark Therapeutics' Luxterna License Outside US
by Zacks Equity Research
Novartis has obtained the marketing rights for Luxterna oustide the United States thereby building upon its gene therapy treatments which includes Kymriah.
Will J&J (JNJ) Witness Deceleration in 2018 Sales Growth?
by Zacks Equity Research
J&J (JNJ) has a history of issuing a cautious outlook, especially at the beginning of the year. However, there are several tailwinds, which can coax it to improve the 2018 projection.
Will Pfizer (PFE) Surpass Estimates This Earnings Season?
by Zacks Equity Research
While Pfizer's (PFE) new drugs like Ibrance and Xeljanz are likely to drive sales in Q4, genericization of key drugs and supply shortages in legacy Hospira products will hurt sales.
Why AbbVie (ABBV) Might Surprise This Earnings Season
by Zacks Equity Research
AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat in the Cards for AbbVie (ABBV) in Q4 Earnings?
by Zacks Equity Research
Impressive sales rise of AbbVie's (ABBV) key drugs, Humira and Imbruvica, might lead the company to an earnings beat in Q4.
Novartis (NVS) Q4 Earnings & Sales Top on Cosentyx, Entresto
by Zacks Equity Research
Novartis (NVS) announced strong results for the fourth quarter as earnings and sales both beat estimates driven by Cosentyx and Entresto sales which more than offset the decline in Gleevec sales.
The Zacks Analyst Blog Highlights: AbbVie, Merck & Co. and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Merck & Co. and AstraZeneca
Will Core Segmental Growth Aid Stryker (SYK) in Q4 Earnings?
by Zacks Equity Research
Stryker's (SYK) robust fundamentals and broad product scale are likely to drive performance in the Q4. However, the company faces product-recall issues.
Novartis Announces Positive Results on Migraine Candidate
by Zacks Equity Research
Novartis announced positive results on migraine candidate, AMG334, from the phase IIIb study. The candidate is being developed in collaboration with Amgen,